Losartan [114798-26-4]
Referencia HY-17512-1g
embalaje : 1g
Marca : MedChemExpress
Please arrange your schedule properly.
- United States
- Canada
- United Kingdom
- Australia
- Germany
- France
- Japan
- Korea South
- Switzerland
- Algeria
- Argentina
- Austria
- Belgium
- Brazil
- Chile
- Croatia
- Czech Republic
- Denmark
- Finland
- Hong Kong, China
- Hungary
- India
- Iraq
- Ireland
- Israel
- Italy
- Lebanon
- Luxembourg
- Malaysia
- Mexico
- Morocco
- Netherlands
- New Zealand
- Norway
- Pakistan
- Peru
- Philippines
- Poland
- Portugal
- Qatar
- Russia
- Saudi Arabia
- Serbia
- Singapore
- Slovakia
- Slovenia
- South Africa
- Spain
- Sweden
- Taiwan, China
- Thailand
- Tunisia
- Turkey
- Ukraine
- Macao, China
- Other Countries
Losartan (Synonyms: DuP-753)
- Cat. No.: HY-17512 Pureza: 99.67%
- COA Instrucciones de manejo
Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
Para uso exclusivo en investigación. No vendemos a pacientes.
Losartan Estructura química
No. CAS : 114798-26-4
Tamaño | Precio | Stock | Cantidad |
---|---|---|---|
Muestra gratis (0.1 - 0.5 mg) | Solicite ahora | ||
Solid + Solvent | |||
10 mM * 1 mL
in DMSO
ready for reconstitution
|
USD 55 | En stock | |
Solution | |||
10 mM * 1 mL in DMSO | USD 55 | En stock | |
Solid | |||
500 mg | USD 50 | En stock | |
1 g | USD 60 | En stock | |
5 g | USD 132 | En stock | |
10 g | Obtener un presupuesto | ||
50 g | Obtener un presupuesto |
* Seleccione Cantidad antes de agregar artículos.
This product is a controlled substance and not for sale in your territory.
Revisión del cliente
Based on 30 publication(s) in Google Scholar
Other Forms of Losartan:
- Losartan Carboxylic Acid In-stock
- Losartan-d4 (carboxylic acid) In-stock
- Losartan potassium In-stock
- Losartan-d4 In-stock
- Losartan-d3 Carboxylic Acid Obtener un presupuesto
- Losartan-d2 Obtener un presupuesto
- Losartan-d9 Obtener un presupuesto
- •Clin Transl Med. 2023 Mar;13(3):e1213. [Abstract]
- •Cell Death Dis. 2020 May 22;11(5):390. [Abstract]
- •J Transl Med. 2024 Jan 5;22(1):26. [Abstract]
- •Oncogene. 2023 Feb 23. [Abstract]
- •Phytomedicine. 2023 Feb 4;112:154700. [Abstract]
- •Phytomedicine. 2022 Mar 21;100:154067. [Abstract]
- •Int J Nanomedicine. 2018 Nov 13;13:7409-7426. [Abstract]
- •J Physiol. 2023 Dec 28. [Abstract]
- •Int Immunopharmacol. 2023 Aug 4;123:110761. [Abstract]
- •Chem Biol Interact. 2023 Jul 14;110636. [Abstract]
- •Biomolecules. 2023 Apr 25, 13(5), 740.
- •Int J Mol Sci. 2023 Feb 3;24(3):2960. [Abstract]
- •Clin Sci. 2021 Mar 26;135(6):793-810. [Abstract]
- •Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F941-F953. [Abstract]
- •Sci Rep. 2019 Dec 19;9(1):19450. [Abstract]
- •FASEB J. 2019 May;33(5):6254-6268. [Abstract]
- •FASEB J. 2018 Sep;32(9):5051-5062. [Abstract]
- •Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H580-H592. [Abstract]
- •J Orthop Surg Res. 2024 Feb 19;19(1):147. [Abstract]
- •Nefrologia. 2023 Sep 6.
- •Gene. 2022 Jan 31;146239. [Abstract]
- •Front Physiol. 2020 Sep 8;11:560170. [Abstract]
- •J Pharmacol Sci. 2020 Sep;144(1):30-42. [Abstract]
- •Arch Biol Sci. 2021 Jun.
- •Friedrich-Alexander University Erlangen-Nuremberg. 2023 May 2.
- •Research Square Print. September 13th, 2022.
- •Oxid Med Cell Longev. 2022 Feb 18;2022:5044046.
- •Rep Biochem Mol Biol. 2021 Jul;10(2):314-326. [Abstract]
- •Reports of Biochemistry and Molecular Biology. 2021 Aug.
-
Losartan purchased from MedChemExpress. Usage Cited in: FASEB J. 2018 Sep;32(9):5051-5062. [Abstract]
- HUVECs are starved for 12 h, treated with 10 mg/mL (9.56 μM) of AngII with or without Losartan or PD123319 for 12 h, and are subsequently used for Western blot analysis.
Ver todos los productos específicos de isoformas Angiotensin Receptor:
Actividad biológica
Protocolo
Pureza y Documentación
Referencias
Revisión del cliente
Descripciòn |
Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target |
|
||||||||||||
In Vitro |
Losartan competes with the binding of angiotensin II to AT1 receptors. The concentration that inhibits 50% of the binding of angiotensin II (IC50) is 20 nM[1]. Losartan (40 μM) affects ISC but prevents the effect of ANGII on ISC[2]. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
In Vivo |
Losartan (0.6 g/L, p.o.) -treated Fbn1C1039G/+ mice show a reduction in distal airspace caliber relative to placebo-treated Fbn1C1039G/+ animals. The doses of losartan and propranolol are titrated to achieve comparable hemodynamic effects. Analysis of pSmad2 nuclear staining reveals that losartan antagonizes TGF-β signaling in the aortic wall of Fbn1C1039G/+ mice. Losartan can improve disease manifestations in the lungs, an event that cannot plausibly relate to improved hemodynamics[4]. Losartan (10 mg/kg, intraarterial injection) increases blood angiotensin levels four- to sixfold. Losartan (10 mg/kg, i.p.) increases plasma renin levels 100-fold; plasma angiotensinogen levels decreases to 24% of control; and plasma aldosterone levels are unchanged[5]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
Ensayo clínico |
|
||||||||||||
Peso molecular |
422.91 |
||||||||||||
Fòrmula |
C22H23ClN6O |
||||||||||||
No. CAS | |||||||||||||
Appearance |
Solid |
||||||||||||
Color |
White to light yellow |
||||||||||||
SMILES |
OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2 |
||||||||||||
Envío | Room temperature in continental US; may vary elsewhere. |
||||||||||||
Almacenamiento |
|
||||||||||||
Solvente y solubilidad |
In Vitro:
DMSO : ≥ 100 mg/mL (236.46 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) *"≥" means soluble, but saturation unknown. Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||
Pureza y Documentación |
Purity: 99.67% |
||||||||||||
Referencias |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 2.3646 mL | 11.8228 mL | 23.6457 mL | 59.1142 mL |
5 mM | 0.4729 mL | 2.3646 mL | 4.7291 mL | 11.8228 mL | |
10 mM | 0.2365 mL | 1.1823 mL | 2.3646 mL | 5.9114 mL | |
15 mM | 0.1576 mL | 0.7882 mL | 1.5764 mL | 3.9409 mL | |
20 mM | 0.1182 mL | 0.5911 mL | 1.1823 mL | 2.9557 mL | |
25 mM | 0.0946 mL | 0.4729 mL | 0.9458 mL | 2.3646 mL | |
30 mM | 0.0788 mL | 0.3941 mL | 0.7882 mL | 1.9705 mL | |
40 mM | 0.0591 mL | 0.2956 mL | 0.5911 mL | 1.4779 mL | |
50 mM | 0.0473 mL | 0.2365 mL | 0.4729 mL | 1.1823 mL | |
60 mM | 0.0394 mL | 0.1970 mL | 0.3941 mL | 0.9852 mL | |
80 mM | 0.0296 mL | 0.1478 mL | 0.2956 mL | 0.7389 mL | |
100 mM | 0.0236 mL | 0.1182 mL | 0.2365 mL | 0.5911 mL |
Losartan Related Classifications
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Productos vistos recientemente:
Consulta en línea
Your information is safe with us. * Required Fields.
Consulta para venta a granel
Inquiry Information
- Nombre del producto:
- Losartan
- Cat. No.:
- HY-17512
- Cantidad:
- MCE Japan Authorized Agent: